Bris­tol My­ers Squib­b's just-launched MS drug Zeposia makes the cut in key ul­cer­a­tive col­i­tis tri­al

In March, Zeposia be­came the third oral S1P mod­u­la­tor to se­cure US ap­proval for mul­ti­ple scle­ro­sis. Now, the drug has suc­ceed­ed in a key ul­cer­a­tive col­i­tis study.

The im­munomod­u­la­tor, akin to oth­ers in its class, con­trols lym­pho­cyte traf­fick­ing by lim­it­ing the white blood cells to the lym­phat­ic sys­tem, in the lymph nodes, and thwart­ing their abil­i­ty to jam up lymph nodes — pre­clud­ing their abil­i­ty to pen­e­trate the blood­stream and the cen­tral ner­vous sys­tem.

In the over 1,000 pa­tient tri­al, chris­tened True North, Zeposia was test­ed against a place­bo as an in­duc­tion and main­te­nance ther­a­py in adults with mod­er­ate-to-se­vere ul­cer­a­tive col­i­tis who did not de­rive enough ben­e­fit from pre­vi­ous ther­a­py. The drug is the first S1P re­cep­tor mod­u­la­tor to demon­strate ben­e­fit in this cat­e­go­ry of pa­tients in a late-stage study, Bris­tol My­ers Squibb said on Tues­day.

The tri­al met both pri­ma­ry end­points: the pro­por­tion of pa­tients in clin­i­cal re­mis­sion based at week 10 in the in­duc­tion phase, and at week 52 for the main­te­nance phase. Zeposia’s ef­fect was high­ly sta­tis­ti­cal­ly sig­nif­i­cant (p-val­ue < 0.0001) the com­pa­ny said, adding that the drug al­so met key sec­ondary end­points.

De­tailed da­ta from the tri­al, as is cus­tom, were not pro­vid­ed at this stage.

Ul­cer­a­tive col­i­tis is a chron­ic in­flam­ma­to­ry bow­el dis­ease and is char­ac­ter­ized by an ab­nor­mal, pro­longed im­mune re­sponse that cre­ates long-last­ing in­flam­ma­tion and ul­cers in the lin­ing of the large in­tes­tine. Apart from steroids and im­muno­sup­pres­sants, oth­er treat­ment op­tions in­clude im­munomod­u­la­tors such as the block­buster TNF in­hibitors Rem­i­cade and Hu­mi­ra.

Zeposia, known chem­i­cal­ly as ozan­i­mod, was ap­proved in March but was on­ly launched days ago due to the Covid-19 out­break. Un­like the first crop of  S1P mod­u­la­tors that in­clud­ed re­quire­ments for dose titra­tion, first dose car­diac mon­i­tor­ing, and oth­er forms of clin­i­cal eval­u­a­tion and/or lab­o­ra­to­ry test­ing, the drug’s la­bel was rel­a­tive­ly be­nign with no black box warn­ing but with con­traindi­ca­tions for some pa­tients with pre-ex­ist­ing heart con­di­tions.

But the MS mar­ket is crowd­ed, and the pace of ap­provals in re­cent years has picked up, in­clud­ing Bio­gen’s Vumer­i­ty, No­var­tis’ Mayzent and EMD Serono’s Maven­clad. So it may be be dif­fi­cult for Zeposia to make a big splash in the mar­ket. So as is the case with many oth­er im­munomod­u­la­tors, the drug is be­ing tri­aled for a host of oth­er im­mune dis­eases, in­clud­ing ul­cer­a­tive col­i­tis and Crohn’s dis­ease.

Ugur Sahin, BioNTech CEO (Bernd von Jutrczenka/dpa via AP Images)

BioN­Tech is spear­head­ing an mR­NA vac­cine de­vel­op­ment pro­gram for malar­ia, with a tech trans­fer planned for Africa

Flush with the success of its mRNA Covid-19 vaccine, BioNTech is now gearing up for one of the biggest challenges in vaccine development — which comes without potential profit.

The German mRNA pioneer says it plans to work on a jab for malaria, then transfer the tech to the African continent, where it will work with partners on developing the manufacturing ops needed to make this and other vaccines.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,900+ biopharma pros reading Endpoints daily — and it's free.

How one start­up fore­told the neu­ro­science re­nais­sance af­ter '50 years of shit­show'

In the past couple of years, something curious has happened: Pharma and VC dollars started gushing into neuroscience research.

Biogen’s controversial new Alzheimer’s drug Aduhelm has been approved on the basis of removing amyloid plaque from the brain, but the new neuro-focused pharma and biotechs have much loftier aims. Significantly curbing or even curing the most notorious disorders would prove the Holy Grail for a complex system that has tied the world’s best drug developers in knots for decades.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Why is On­col­o­gy Drug De­vel­op­ment Re­search Late to the Dig­i­tal Bio­mark­ers Game?

During the recent Annual ASCO Meeting, thousands of cancer researchers and clinicians from across the globe joined together virtually to present and discuss the latest findings and breakthroughs in cancer research and care. There were more than 5000+ scientific abstracts presented during this event, yet only a handful involved the use of motion-tracking wearables to collect digital measures relating to activity, sleep, mobility, functional status, and/or quality of life. Although these results were a bit disappointing, they should come as no surprise to those of us in the wearable technology field.

Art Levinson (Calico)

Google-backed Cal­i­co dou­bles down on an­ti-ag­ing R&D pact with Ab­b­Vie as part­ners ante up $1B, start to de­tail drug tar­gets

Seven years after striking up a major R&D alliance, AbbVie and Google-backed anti-aging specialist Calico are doubling down on their work with a joint, $1 billion commitment to continuing their work together. And they’re also beginning to offer some details on where this project is taking them in the clinic.

According to their statement, each of the two players is putting up $500 million more to keep the labs humming.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,900+ biopharma pros reading Endpoints daily — and it's free.

Bob Bradway, Amgen CEO (Scott Eisen/Bloomberg via Getty Images)

Am­gen bel­lies back up to the M&A ta­ble for an­oth­er biotech buy­out, this time with a $2.5B deal for an an­ti­body play­er fo­cused on PS­MA

Five months after Amgen CEO Bob Bradway stepped up to the M&A table and acquired Five Prime for $1.9 billion, following up with the smaller Rodeo acquisition, he’s gone back in for another biotech buyout.

This time around, Amgen is paying $900 million cash while committing up to $1.6 billion in milestones to bag the privately held Teneobio, an antibody drug developer that has expertise in developing new bispecifics and multispecifics. In addition, Amgen cited Teneobio’s “T-cell engager platform, which expands on Amgen’s existing leadership position in bispecific T-cell engagers by providing a differentiated, but complementary, approach to Amgen’s current BiTE platform.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,900+ biopharma pros reading Endpoints daily — and it's free.

Eye­ing quick ap­proval, Ab­b­Vie of­fers a close-up on their pres­by­opia drug da­ta

AbbVie picked up some bonus points earlier this year as one of its pipeline adds from the $63 billion Allergan buyout hit its top-line marks. And now the researchers have produced the detailed data on the case they are making with regulators, with an eye on a major new market and a hoped-for approval before New Year’s.

AGN-190584 is aiming to be the first easy-on eyedrop for presbyopia, a common ailment for large numbers of people who find it harder and harder to read things like a watch or cell phone close up. Anyone who’s held a book out at arm’s length in order to read it will be very familiar with the condition, if not the exact diagnosis.

Ryan Watts, Denali CEO

De­nali slips as a snap­shot of ear­ly da­ta rais­es some trou­bling ques­tions on its pi­o­neer­ing blood-brain bar­ri­er neu­ro work

Denali Therapeutics had drummed up considerable hype for their blood-brain barrier technology since launching over six years ago, hype that’s only intensified in the last 14 months following the publications of a pair of papers last spring and proof of concept data earlier this year. On Sunday, the South San Francisco-based biotech gave the biopharma world the next look at in-human data for its lead candidate in Hunter syndrome.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,900+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Pan­el of neu­ro­science ex­perts lays out the com­pli­ca­tions with us­ing Bio­gen's new Alzheimer's drug

Treatment of early Alzheimer’s patients with Biogen’s new drug Aduhelm should closely resemble how the drug was studied in its pivotal clinical trials, according to new recommendations from a panel of neuroscience experts led by UNLV’s Jeffrey Cummings.

“Those considering aducanumab therapy should understand that the expected benefit is slowing of cognitive and functional decline; improvement of the current clinical state is not anticipated,” they wrote Tuesday in The Journal of Prevention of Alzheimer’s Disease, noting that some of their recommendations are more specific or more restrictive than the information provided in the FDA’s prescribing information.

Christophe Weber, Takeda CEO (Kyodo via AP Images)

Take­da flesh­es out CNS pact with pep­tide drug­mak­er, set­ting aside $3.5B in fu­ture mile­stones

One of a suite of drugmakers looking to reinvest in the neuroscience space, Takeda has been aggressive in signing on new partners to help build up its pipeline in that space. But sometimes the best partner is the one you already have.

Takeda will set aside $3.5 billion in future milestones and an undisclosed upfront payment to build out its drug discovery deal with Japanese peptide conjugate maker PeptiDream, adding neurodegeneration to the partnership’s list of CNS targets, the companies said Tuesday.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,900+ biopharma pros reading Endpoints daily — and it's free.